伴随着国产GLP-1减重药玛仕度肽（商品名：信尔美）的商业化落地国内减重药市场格局迎来了新的变化。全球两大减重药巨头诺和

智通财经2025-07-06

伴随着国产GLP-1减重药玛仕度肽（商品名：信尔美）的商业化落地国内减重药市场格局迎来了新的变化。全球两大减重药巨头诺和诺德与礼来在中国市场将面临更激烈的竞争环境减重药未来价格是否会出现松动也引发关注。 7月3日信达生物的GLP-1减重创新药玛仕度肽“首方”落地。北京大学人民医院分泌科主任医师纪立农教授为一名超重合并脂肪肝的患者开出全国首张处方标志着玛仕度肽正式进入国内公立医院。这距离该药物获批仅...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2549327269?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-07-06 19:41","share_image_url":"https://static.laohu8.com/6ca2dcdccfa2217fb20a0351f4efe814","id":"2549327269","market":"us","top_or_hot":-1,"title":"伴随着国产GLP-1减重药玛仕度肽（商品名：信尔美）的商业化落地国内减重药市场格局迎来了新的变化。全球两大减重药巨头诺和","media":"智通财经","content":"<div>\n<p>伴随着国产GLP-1减重药玛仕度肽（商品名：信尔美）的商业化落地国内减重药市场格局迎来了新的变化。全球两大减重药巨头诺和诺德与礼来在中国市场将面临更激烈的竞争环境减重药未来价格是否会出现松动也引发关注。 7月3日信达生物的GLP-1减重创新药玛仕度肽“首方”落地。北京大学人民医院分泌科主任医师纪立农教授为一名超重合并脂肪肝的患者开出全国首张处方标志着玛仕度肽正式进入国内公立医院。这距离该药物获批仅...</p>\n\n<a href=\"https://www.zhitongcaijing.com/immediately.html?type=usstock\">网页链接</a>\n\n</div>\n","source":"live_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>伴随着国产GLP-1减重药玛仕度肽（商品名：信尔美）的商业化落地国内减重药市场格局迎来了新的变化。全球两大减重药巨头诺和</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n伴随着国产GLP-1减重药玛仕度肽（商品名：信尔美）的商业化落地国内减重药市场格局迎来了新的变化。全球两大减重药巨头诺和\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-07-06 19:41 北京时间&nbsp;&nbsp;&nbsp;<a href=https://www.zhitongcaijing.com/immediately.html?type=usstock><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>伴随着国产GLP-1减重药玛仕度肽（商品名：信尔美）的商业化落地国内减重药市场格局迎来了新的变化。全球两大减重药巨头诺和诺德与礼来在中国市场将面临更激烈的竞争环境减重药未来价格是否会出现松动也引发关注。 7月3日信达生物的GLP-1减重创新药玛仕度肽“首方”落地。北京大学人民医院分泌科主任医师纪立农教授为一名超重合并脂肪肝的患者开出全国首张处方标志着玛仕度肽正式进入国内公立医院。这距离该药物获批仅...</p>\n\n<a href=\"https://www.zhitongcaijing.com/immediately.html?type=usstock\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"GLP","symbol_name":"Global Partners Lp","start_time":0,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","article_id":"2549327269","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2549327269","pubTimestamp":1751802085,"columns":[],"sourceInfo":{"source_id":"live_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"伴随着国产GLP-1减重药玛仕度肽（商品名：信尔美）的商业化落地国内减重药市场格局迎来了新的变化。全球两大减重药巨头诺和诺德与礼来在中国市场将面临更激烈的竞争环境减重药未来价格是否会出现松动也引发关注","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"159992":"创新药","GLP":"Global Partners Lp","LLY":"礼来","LU1069344957.HKD":"AB SICAV I - AMERICAN GROWTH PORTFOLIO \"AD\" (HKD) INC","LU2237438978.USD":"Amundi Funds US Pioneer A2 (C) USD","LU2063271972.USD":"富兰克林创新领域基金","BK4532":"文艺复兴科技持仓","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","BK4581":"高盛持仓","BK4599":"减肥药","YINN":"三倍做多富时中国ETF-Direxion","LU0354030438.USD":"富国美国大盘成长基金Cl A Acc","LU1868837300.USD":"CT (LUX) I AMERICAN FUND \"9\" (USD) ACC","LU2237443895.HKD":"abrdn SICAV I -  GLOBAL DYNAMIC DIVIDEND \"A\" (HKD) ACC","LU2237443465.HKD":"abrdn SICAV I -  GLOBAL DYNAMIC DIVIDEND \"A\" (HKD) INC","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","LU2236285917.USD":"ALLIANZ GLOBAL INCOME \"AMG\" (USD) INC","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","06978":"永泰生物-B","BK1574":"生物医药B类股","LU0320765059.SGD":"FTIF - Franklin US Opportunities A Acc SGD","SGXZ81514606.USD":"大华环球创新基金A Acc USD","IE00BJLML261.HKD":"HSBC GLOBAL EQUITY INDEX \"HCH\" (HKD) ACC","LU0672654240.SGD":"FTIF - Franklin US Opportunities A Acc SGD-H1","LU1917777945.USD":"安联专题基金Cl AT Acc","SG9999014914.USD":"UNITED GLOBAL QUALITY GROWTH (USDHDG) INC","NVO":"诺和诺德","SG9999015952.SGD":"LIONGLOBAL DISRUPTIVE INNOVATION \"I\" (SGD) ACC","LU2552382215.SGD":"WELLINGTON US BRAND POWER \"A\" (SGDHDG) ACC","LU0094547139.USD":"abrdn SICAV I - GLOBAL SUSTAINABLE EQUITY FUND \"A\" (USD) ACC","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","LU2471134952.CNY":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (CNYHDG) INC","GB00BDT5M118.USD":"天利环球扩展Alpha基金A Acc","IE00BK4W5M84.HKD":"HSBC GLOBAL FUNDS ICAV US EQUITY INDEX \"HC\" (HKD) ACC","LU2361044865.SGD":"WELLINGTON US QUALITY GROWTH \"A\" (SGDHDG) ACC","LU2552382132.HKD":"WELLINGTON US BRAND POWER \"A\" (HKD) ACC","LU0256863811.USD":"ALLIANZ US EQUITY \"A\" INC","BK4588":"碎股","BK1589":"北水核心资产","SG9999015978.USD":"利安颠覆性创新基金A","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","LU0689472784.USD":"安联收益及增长基金Cl AM AT Acc","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","01801":"信达生物","IE00B1BXHZ80.USD":"Legg Mason ClearBridge - US Appreciation A Acc USD","LU2361045086.USD":"WELLINGTON US QUALITY GROWTH \"A\" (USD) ACC","LU2471134796.USD":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (USD) INC","LU0096364046.USD":"CT (LUX) I AMERICAN \"DU\" (USD) ACC","LU0122379950.USD":"贝莱德世界健康科学A2","LU1989771016.USD":"东方汇理环球老龄化投资基金 A2 Acc"},"translate_title":"With the commercialization of the domestic GLP-1 weight loss drug Masidoptide (trade name: Xinermei), the domestic weight loss drug market structure has ushered in new changes. Novo, the world's two largest weight loss drug giants","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159992":1,"NVO":1,"06978":1,"GLP":1,"YINN":1,"01801":1,"LLY":1},"content_text":"伴随着国产GLP-1减重药玛仕度肽（商品名：信尔美）的商业化落地国内减重药市场格局迎来了新的变化。全球两大减重药巨头诺和诺德与礼来在中国市场将面临更激烈的竞争环境减重药未来价格是否会出现松动也引发关注。 7月3日信达生物的GLP-1减重创新药玛仕度肽“首方”落地。北京大学人民医院分泌科主任医师纪立农教授为一名超重合并脂肪肝的患者开出全国首张处方标志着玛仕度肽正式进入国内公立医院。这距离该药物获批仅一周之隔。下周起该药物将陆续进入全国各大公立医院。 相比之下诺和诺德的司美格鲁肽减重适应症（商品名：诺和盈）从获批到正式商业化开出公立医院“首方”历时近5个月；礼来的替尔泊肽减重适应症从获批到上市也经历了近半年时间。 “国内厂商没有产能供应限制的问题。”一位业内人士对第一财经记者。另据记者了解直到目前为止司美格鲁肽与替尔泊肽均尚未在国内实现本土化生产。（第一财经）。","kind":"live","is_publish_news":false,"is_publish_highlight":false,"is_publish_live":true,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2549327269","isCrawlerRequest":true}